OP Asset Management Ltd Takes Position in Enovis Corporation $ENOV

OP Asset Management Ltd purchased a new stake in Enovis Corporation (NYSE:ENOV) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 40,910 shares of the company’s stock, valued at approximately $931,000. OP Asset Management Ltd owned about 0.07% of Enovis at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. Arax Advisory Partners purchased a new stake in Enovis during the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares during the period. Danske Bank A S bought a new position in shares of Enovis during the 3rd quarter valued at approximately $64,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Enovis during the 3rd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ENOV. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a research note on Sunday. William Blair began coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Finally, Wells Fargo & Company dropped their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Insider Buying and Selling

In related news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have bought 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Enovis Price Performance

ENOV opened at $21.99 on Tuesday. The business has a fifty day moving average of $23.51 and a 200 day moving average of $24.00. The stock has a market cap of $1.27 billion, a P/E ratio of -1.11 and a beta of 1.38. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis Corporation has a 52-week low of $20.55 and a 52-week high of $36.82.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts anticipate that Enovis Corporation will post 3.65 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.